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ABSTRACT  
 
Analytical proteomics has experienced exponential progress in the last decade and can 
be expected to lead research studies on diagnostic and therapeutic biomarkers in the 
near future. Because the development of this type of analysis requires the use of a large 
number of human samples with a minimum of quality requirements, our objective was 
to identify appropriate indicators for quality control of plasma samples stored in 
biobanks for research in proteomics. To accomplish this, plasma samples from 100 
healthy donors were obtained and processed according to the pre-analytical variables of: 
a) time delay for the first centrifugation of the original blood sample (4 or 24 hours) and 
b) number of freeze/thaw cycles (1, 2 or 3) of the processed plasma samples. The 
analyses of samples were   performed by different and complementary methods such as 
SPE MALDI-TOF, DIGE, shotgun (iTRAQ, nLC MALDI TOF/TOF) and targeted nLC 
MS/MS proteomic techniques (SRM). In general, because the distribution of proteins in 
all samples was found to be very similar, the results shown that delayed processing of 
blood samples and the number of freeze/thaw cycles has little or no effect on the 
integrity of proteins in the plasma samples. 
SIGNIFICANCE 
The results of the present work indicate that blood proteins in plasma are broadly 
insensitive to such preanalytical variables as delayed processing or freeze/thaw cycles 
when analyzed at the peptide level. Although there are other studies related to protein 
stability of clinical samples with similar results, what is remarkable about our work is 
the large number of plasma samples examined and that our analyses assessed protein 
integrity by combining a wide set of complementary proteomic approaches performed at 
different proteomic platform participating laboratories that all yielded similar results. 
We believe our study is the most comprehensive performed to date to determine the 
changes in proteins induced by delayed sample processing and plasma freeze/thaw 
cycles. 
 
 
Keywords: Plasma, proteomics, biobank, sample, pre-analytical variables    
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INTRODUCTION 
 
The remarkable proliferation in biomedical research taking place is driving the need for 
increased quality of storage and handling of large numbers of biological samples, 
including tissues, tumors, cells, proteins, DNA, blood, serum, and urine, to insure 
suitability for further studies [1]. Biobanks house collections of biological samples 
intended for diagnostic or biomedical research and have the proper infrastructure and 
technology to ensure high quality of the samples [2]. To facilitate establishment of 
collaborations and joint projects among different researchers, biobanks collect samples 
from donors with a specific pathology and from healthy controls to reduce turnaround 
time and validation of investigations [3]. However, the sizeable storage of biological 
samples raises complex technical issues that affect different procedural steps, including, 
among others, sample collection, transport, identification, traceability, storage at 
different temperatures, recovery of the stored sample and processing of the data. 
Because it is essential that information on the handling of biological materials be 
complete and accurate, it is necessary to develop standardized protocols [4].  
 
Heterogeneity in sampling and storage procedures can introduce significant variability 
in the molecular composition of biological samples, thus interfering with or affecting 
reproducibility [5]. This issue becomes even more evident in research studies in which 
biological samples from different origins are employed. In fact, some authors have 
shown that differences detected in retrospective collections of biological samples are 
more dependent on pre-analytical factors (e.g., processes taking place at different points 
of the experimental workflow) than on the inherent differences among the samples [6]. 
For example, the Biospecimen Science Working Group of the ISBER (International 
Society for Biospecimen Science) [7] retrospectively reviewed several research studies 
using stored biological samples. They found that the heterogeneity in the protocols for 
collection and storage made it very difficult to draw reliable conclusions about the 
usefulness of the samples for the identification of biomarkers. Therefore, the 
identification of clinically relevant biomarkers can only be successful if biological 
samples are obtained, processed and stored according to strict standard protocols [8,                                                                                                                                                     
9]. 
 
Furthermore, in parallel with the definition of a standard protocol for collection and 
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storage of biological samples, it is essential to identify specific biomarkers that can be 
used as quality controls to assess the effects of pre-analytical factors on variability in the 
results [10]. However, quality criteria cannot be specifically defined because they are 
dependent both on the sample type and the experimental purpose.  
 
Plasma from human subjects is a promising source for biological markers of disease 
[11], it is a complex biological fluid containing various biomolecules (lipids, peptides, 
amino acids, cytokines, proteases, enzymes, antibodies, etc.) with very different 
physicochemical properties. Despite progress made in the study of the plasma proteome, 
to date, no usable protein markers for monitoring the quality of these samples have been 
described. Thus, it is necessary to define a panel of protein markers that establishes 
minimal quality standards for the analytical phase and excludes those samples whose 
integrity is compromised by a defective pre-analytical phase [12]. Among the variables 
involved in the collection, processing and storage procedures, we must first examine 
those that potentially compromise the quality of the samples and establish a set of 
parameters aimed at reducing variability at critical sampling points.  
 
Following blood sample extraction, the critical variables to consider include the time 
between sample collection and processing, the freezing protocol and freezing 
temperature, the storage duration and number of freeze/thaw cycles. In the time lapse 
between sample collection and processing, modifications of peptides and proteins or 
release of cell-derived substances may occur, suggesting that shorter processing times 
correlate with more reliable samples [13,14]. For example, serum values of the CD40 
ligand increased with delayed processing and prolonged storage of serum samples or 
decreased after prolonged storage of serum samples at elevated temperature [15]. The 
effect of repeated freeze-thaw cycles on sera was also analyzed in an inconclusive 
attempt to find a marker for the quality of serum cryopreservation [16]. Another 
important factor potentially affecting quality and stability of samples is storage time 
[17] and temperature [18]. It is known that some biomarkers are not sensitive to 
prolonged or inappropriate temperature storage, but others may degrade spontaneously. 
In spite of all the above-mentioned studies, we conclude that, thus far, the search for 
potential quality control indicators for plasma proteomics is far from completion. 
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Analytical proteomics has experienced extensive progress in the last decade because of 
the emergence of MS-based techniques (MALDI-TOF, iTRAQ) that combined with 
classical techniques for protein separation (e.g., chromatography, two-dimensional gel 
electrophoresis, etc.) facilitate the identification and characterization of proteins. 
Proteomics is expected to be the tool of choice for the search for diagnostic or 
therapeutic biomarkers and for the identification and characterization of the proteins 
encoded by the genome [19]. One of the main objectives of proteomics is the 
identification of markers of disease by comparing the protein status in normal and 
pathological conditions. It is noteworthy that the control of pre-analytical effects, which 
can produce a significant influence on the results of analyses, is a critical point for 
proteomic studies [5, 20].  
 
By using different complementary proteomic techniques in separate coordinated 
laboratories, the aim of this study was to search for quality markers that would allow 
assessment of the integrity and purity of plasma proteome samples. Thus, 
recommendations could be established to include or exclude samples of plasma for 
proteomic studies according to their quality parameters. 
 
MATERIALS AND METHODS 
 
DESIGN OF THE STUDY AND DONORS 
 
The study was carried out using prospectively obtained peripheral blood samples from a 
cohort of healthy donors through participation of seven different Spanish Biobanking 
Facilities. The sample population (n=100) was comprised of 50 men and 50 women. 
Distribution by age of the cohort was 20-40 (n=40), 40-60 (n=40), and 60-80 (n=20) 
years. This study was approved by the Ethics Committee of Clinical Investigation of 
Galicia (Spain). 
 
COLLECTION OF PLASMA SAMPLES FROM PERIPHERAL BLOOD 
 
EDTA-Blood samples (40 ml) from each donor were obtained and processed by the 
participating biobanks applying the same standard operating procedure (SOP) for 
collection and storage of platelet-poor plasma. The SOP was based on the 
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recommendations of the Human Proteome Organization (HUPO) [12], but including 
some variables detailed in the next section. Once obtained, the plasma samples were 
distributed into 200 µl aliquots (ProteinLoBind Tube 0.5 ml, Eppendorf AG
©
, 
Germany) and stored at -80°C for later analysis. 
 
VARIABLES STUDIED 
 
Briefly, EDTA-blood tubes were subjected to different pre-analytical conditions 
according to the following variables:  
1) Time between blood collection and processing, to evaluate the effect of the delay in 
the first centrifugation step in plasma protein composition. Two conditions were 
considered: a) Delay of less than four hours at room temperature after blood extraction 
(t≤4h) (representative of the daily routine of a laboratory of clinical analysis that 
process local samples) or b) 24 hours delay (t=24h) at 4º C (reflecting those samples 
arriving from external laboratories).  
2) Repeated freeze/thaw cycles, to evaluate the influence of this variable on plasma 
protein integrity. To that end, plasma samples (t≤4h) were subjected to 1, 2 and 3 cycles 
of freezing and thawing. Thawing was performed leaving the samples for 1h at room 
temperature. Thawing was for one hour at room temperature with any subsequent 
freeze/thaw cycle done after 24 h. 
 
For proteomics analyses, samples were pooled and compared as follows: a) Mix of 100 
plasma samples (t≤4h) that were subjected to one (P4.D1); two (P4.D2); or three 
freeze/thaw cycles (P4.D3); or b) mix of 100 plasma samples (t=24h) subjected to one 
cycle of freezing and thawing (P24.D1). Fig. 1 summarizes the whole work-flow. 
 
IMMUNODEPLETION OF ABUNDANT PROTEINS 
 
Prior to the proteomic analysis, pooled plasma samples were depleted of the most 
abundant plasma proteins using commercial immunoaffinity columns. Briefly, 30 µL of 
each sample pool was diluted to a final volume of 240 µL with mobile phase A (Agilent 
Technologies
©
, Santa Clara, CA, USA) and filtered through a 0.22 μm cellulose acetate 
membrane (CLS810, Costar Spin-X, Corning
©
, Tokyo, Japan) at 5000 x g for 15 
minutes to remove insoluble material and debris. The filtered flow-through was 
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collected and processed to deplete the fourteen most abundant plasma proteins using a 
M.A.R.S. Hu-14 (Agilent Technologies) in a 1200 HPLC system (Agilent, Wilmington, 
DE, USA), following the manufacturer's instructions.  Individual 150 μL injections were 
performed and the flow-through fractions (non-binding proteins) containing the lower-
abundance proteins were collected in a final volume of approximately 600 μL. The 
protein concentration was determined by direct absorbance measurement at 280 nm. 
Samples were then aliquoted and stored at -80
o
C until delivery to the participating 
laboratories. 
 
SOLID PHASE EXTRACTION (SPE) AND MALDI-TOF-TOF MS ANALYSIS 
 
After delivery, the depleted plasma samples were stored at -80ºC. Protein 
concentrations were normalized at 1 mg/mL (+/- 5%) by the addition of 0.1% 
trifluoroacetic acid (TFA) from Pierce (Thermo Fisher Scientific Inc
©
, Waltham, MA, 
USA) in water. The samples were divided into two sets, one set for each of the two SPE 
methods, using two different ZipTip (EMD Millipore
©
, Billerica, MA) affinities: C4 
and C18 reverse phase resins. 4 μL of each sample were added for each ZipTip affinity, 
and the flow-through was discarded. Following this step, samples were washed with 4 
μL 0.1% TFA, and finally, the peptides were eluted from the microcolumns with 4 μL 
of HCCA matrix (Alfa-Aesar
©
 Karlsruhe, DE), 5 mg/mL in 70:30 ACN:0.1% TFA, 
onto a 0.5 mL Eppendorf tube (Eppendorf AG
©
, Germany). Four technical replicates of 
1 μL for each sample were spotted, 1 μL each, onto an Anchorchip 800/384 (Bruker 
Daltonics
©
, Bremen, DE) MALDI target.  
 
An Autoflex III MALDI-TOF mass spectrometer was used in linear geometry for 
spectra acquisition up to 20.000 Th as previously described [21,22]. Spectral 
representation was made using ClinProt Tools 2.2 (Bruker Daltonics
©
, Bremen, DE) 
software. Spectra were mathematically processed by the following: baseline correction 
with Top Hat algorithm (using 5.0% of minimal linear base); smoothing with Savitsky-
Golay algorithm (using peak width of 2.0 (m/z) and 5 processing cycles); and 
recalibration using up to 10 of the most intense peaks. 
 
DIFFERENTIAL GEL ELECTROPHORESIS (DIGE) AND LC-MS/MS ANALYSIS 
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Two-dimensional (2D)-DIGE 
Fifty µg of each depleted pooled-plasma sample was labeled with 400 pmol of CyDye 
DIGE Fluor minimal dyes (GE Healthcare
©
, Little Chalfont, UK) according to the 
manufacturer’s instructions (Cy3 and Cy5 for samples and Cy2 for an internal control 
using equal parts of all samples). Pairs of samples were reverse-labeled to eliminate the 
possibility of dye-labeling bias and then resolved by 2D-DIGE as previously described 
[23]. Following Decyder analysis, differential spots were selected for protein 
identification when the p-value after ANOVA or t-test was <0.05. Proteins were 
visualized by staining with SYPRO Ruby Protein Gel Stain (Bio-Rad, Hercules, CA, 
USA) and differentially identified spots were excised manually. In-gel tryptic digestion 
was performed using 10 ng/µl sequencing grade modified trypsin (Promega 
Corporation
©
, Madison, WI, USA) in 50 mM ammonium bicarbonate overnight at 37ºC, 
after denaturation with DTT (10 mM, 30 min, 40ºC) and an alkylation step with 
iodoacetamide (25 mM, 30 min, room temperature). The resulting peptides were 
extracted with 1% formic acid, 50% ACN and evaporated to dryness prior to LC-
MS/MS analysis. 
 
LC-MS/MS analysis  
For each spot, a total volume of 5 μl of the solution of tryptic digestion peptides was 
injected with a flow rate of 300 nL/min in a nanoLC Ultra1D plus (ABSciex
©
, 
Framingham, MA, USA). A trap column, the Acclaim PepMap100 (100 µm x 2 cm; 
C18, 2 µm, 100Å) and an analytical column, the  Acclaim PepMap RSLC (75 µm x 15 
cm, C18, 5 µm, 100 Å) from Thermo Scientific (Thermo Fisher Scientific Inc
©
, 
Waltham, MA, USA) were used following the next gradient: 0–1 min (5% B), 1-50 min 
(5–40% B), 50-51 min (40-98% B), 51-55 min (98% B), 55-56 min (5% B), 56-75 min 
(5% B). (Buffer B: 100% ACN, 0.1% formic acid, Buffer A: 0.1% formic acid). MS 
analysis was performed on a Q-TRAP 5500 system (ABSciex, Sciex
©
, Framingham, 
MA, USA) with a NanoSpray® III ion source (ABSciex) using Rolling Collision 
Energy in positive mode. MS/MS data acquisition was performed using Analyst 1.5.2 
(AB Sciex) and submitted to Protein Pilot software (ABSciex) against 
UniprotKB/Swiss-Prot database, using the Paragon™ Algorithm and the pre-established 
search parameters for 5500 QTRAP. 
 
ITRAQ  ANALYSIS  
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Trypsin digestion and iTRAQ labeling 
 
12 ug of protein from each depleted plasma sample were precipitated using the 
methanol/chloroform method. Protein pellets were resuspended and denatured in 20 µl 7 
M urea, 2 M thiourea, 100 mM triethylammonium bicarbonate (TEAB) buffer, pH 7.5, 
reduced with 2 µL of 50 mM TCEP ((tris-(2-carboxyethyl)phosphine; ABSciex
©
, 
Framingham, MA, USA), pH 8.0, at 37°C for 60 min. Cysteines were then blocked by 
incubation with 1 µl of 200 mM methyl methanethiosulfonate (MMTS; Pierce, Thermo 
Fisher Scientific Inc
©
, Waltham, MA, USA). for 10 min at room temperature. Samples 
were diluted up to 140 µL to reduce urea concentration with 25 mM TEAB. Trypsin 
(Sigma-Aldrich Co
©
, Saint Louis, MO, USA) was added at a 1:20 ratio and digestion 
was left to proceed overnight at 37°C. The resulting peptides were subsequently labeled 
using the iTRAQ 4-plex kit (ABSciex
©
, Framingham, MA, USA) following 
manufacturer's instructions and identified: P4.D1, tag-114; P4.D2, tag-115; P4.D3, tag-
116 and P24.D1, tag-117. After labeling, the samples were pooled, speedvac dried and 
stored at -20°C for further analysis. 
 
Reversed phase HPLC 
The iTRAQ labeled peptides were fractionated by basic rpHPLC in a SmartLine 
(Knauer) HPLC system using an XBridge C18 column (100 × 2.1 mm, 5 μm particle 
diameter; Waters). Solvent A was 10 mM ammonium hydroxide (pH 9.4); and solvent 
B was 80% methanol, 10 mM ammonium hydroxide (pH 9.3). Peptides were 
fractionated using a linear gradient of 0–100% buffer B at 150 μL/min for 90 min. 
Thirty fractions were collected and pooled into 5 fractions using the fraction mixing 
strategy n+1 (i.e., fractions 1+6+11+16+21+26). The peptide fractions were vacuum-
dried, desalted using a SEP-PAK C18 Cartridge (Waters) and stored at −20°C before 
LC-MS analysis. 
 
LC-ESI-MS/MS and data analysis 
A 2 µg aliquot of each resulting fraction was subjected to LC-ESI-MS/MS analysis as 
described elsewhere [24], using a nanoLC Ultra 1D plus (ABSciex
©
, Framingham, MA, 
USA) coupled online to a 5600 Triple TOF mass spectrometer (ABSciex
©
, 
Framingham, MA, USA). The MS and MS/MS data obtained were analyzed as a 
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previously described workflow [24]. The confidence interval for protein identification 
was set to ≥95% (p<0.05) and peptides were filtered at a false discovery rate (FDR) ≤ 
1%. For the quantitative analysis a 5% FDR threshold was applied. 
 
SDS-PAGE FOLLOWED BY LC-ESI-MSMS  
 
Protein separation by SDS/PAGE and trypsin digestion 
Individual depleted pooled plasma samples containing 50 μg of protein were loaded 
onto and separated by pre-cast tris-gly gels of 4-20 % polyacrylamid (Thermo Fisher 
Scientific Inc
©
, Waltham, MA, USA ). After electrophoresis, the gels were stained with 
Coomassie blue and each lane was sliced just below the 20 kDa marker. Samples were 
digested with sequencing grade trypsin (Promega Corporation
©
, Madison, WI, USA) as 
described elsewhere [25]. The digestion was stopped with TFA (1% final concentration) 
and a double peptide extraction was done with ACN. The peptides were dried and 
dissolved with 9 µL of 2% ACN; 0.1% TFA. 
 
LC-MS/MS analysis  
The peptides were then analyzed by LC-MS/MS by loading 5 µl of each sample onto a 
trap column (NanoLC Column, 3 µ C18-CL, 75 µm x 15 cm ; ABSciex
©
, Framingham, 
MA, USA) and desalted with 0.1% TFA at 2 µl/min for 10 min. Afterwards, the 
peptides were transferred onto an analytical column (LC Column, 3 µ C18-CL, 75 µm x 
25 cm, ABSciex
©
, Framingham, MA, USA) equilibrated in 5% ACN 0.1% formic acid 
(FA). Elution was carried out with a linear gradient of 5-35% B (ACN, 0.1% FA) in A 
(0.1% FA) for 60 min at a flow rate of 300 nl/min.  Peptides were analyzed in a mass 
spectrometer nanoESI qQTOF (5600 TripleTOF, ABSciex
©
, Framingham, MA, USA).  
The tripleTOF was operated in an information-dependent acquisition mode, in which a 
0.25-s TOF MS scan from 350–1250 m/z, was performed, followed by 50 ms product 
ion scans from 100–1500 m/z on the 50 most intense 2-5 charged ions. 
 
Protein identification was performed with ProteinPilot v4.5 search engine (ABSciex©, 
Framingham, MA, USA).   ProteinPilot default parameters were used to generate a peak 
list directly from 5600 TripleTof wiff files. The Paragon algorithm of ProteinPilot was 
used to search the Expasy protein database with the following parameters: trypsin 
specificity, cys-alkylation, taxonomy restricted to human, and the search effort set to 
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“thorough”. Identified proteins were grouped in quartiles according to their expected 
molecular weights. The number of proteins and the coverage in each quartile were 
determined. 
 
LC-MALDI-TOF/TOF  
 
Protein separation by SDS-PAGE  
Individual depleted pooled-plasma samples of 30 μg of protein for each pool, in 
triplicate, were loaded and separated by SDS-PAGE in 10% acrylamide in-house gels in 
a Protean® mini-gel system (Bio-Rad, Hercules, CA, USA).  Following Coomassie blue 
staining to check protein integrity, each lane was size-fractioned into 6 sections below 
the 65 KDa molecular weight marker. Sections were subsequently processed 
independently. Each section was de-stained with methanol, diced into small pieces and 
in-gel digested following standard procedures [24]. Peptides were then extracted, 
vacuum-dried, reconstituted in 0.1% TFA and de-salted using home-made stage-tips 
[26]. 
 
LC- MALDI-TOF/TOF analysis 
 
Peptide fractions were separated using reversed phase chromatography in a nanoLC 
system (Tempo, Eksigent, Dublin, CA, USA) by loading through a trapping column into 
a C18 silica based column (New Objective, Woburn, MA, USA) with an internal 
diameter of 75 µm and a pore size of 300 Å. Peptides were eluted at a flow rate of 0.35 
μL/min during a 1 hour linear gradient from 2 to 36% ACN (mobile phase A: (0.1% 
TFA, 2% ACN; mobile phase B: 0.1% TFA, 95% ACN), mixed with α-cyano matrix (4 
mg/mL at a flow rate of 1.2 μL/min) and deposited onto a MALDI plate using an 
automatic spotter (SunCollect, Sunchrome, Friedrichsdorf, Germany). Chromatograms 
corresponding to each gel section were composed of 240 spots, each one comprising a 
15 s deposition. The MS runs for each chromatogram were acquired and analyzed in a 
MALDI-TOF/TOF instrument 4800 (ABSciex, Sciex©, Framingham, MA, USA) using 
a fixed laser intensity of 3400 kV and 1000 shots/spectrum. Automated precursor 
selection was done using a Job-Wide interpretation method (up to 20 precursors per 
fraction with a signal-to-noise lower threshold of 50) with a laser voltage of 4400 and 
2000 shots/spectrum at medium CID collision energy range.  
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The complete MS and MS/MS raw data were processed and peptide identification was 
performed against uniprot_sprot database (Release 2015_07 with 548,872 entries) using 
the Mascot server on-line (www.matrixscience.com). Search parameters included 
carbamidomethylation of cysteines (fixed modification), oxidation of methionine 
(variable modification, ≤4), up to one trypsin miscleavage, precursor ion mass range 
800–4000 Da, ±50 ppm tolerance on precursor and ±0.3 Da on fragmentation of ions. A 
Mascot server was used to calculate the exponentially modified protein abundance 
index (emPAI) [27] as an estimation of the absolute protein amount. The individual 
emPAI indexes from each of the three experimental replicates were then used to 
calculate an average emPAI index for each protein. 
 
SELECTED REACTION MONITORING (SRM)  
 
Proteins from depleted plasma samples were precipitated (Ready Prep Cleanup Kit-
BioRad) and the pellet was resuspended in 7 M urea and diluted 1:10 with 50 mM 
ammonium bicarbonate. 20 μg of protein was digested overnight as indicated 
previously. Peptide desalting, concentration and purification were performed using C18 
ZipTip® pipette tips (Millipore), according to the manufacturer’s instructions. The 
peptides were resuspended in 2% ACN / 0.1% formic acid. Each sample was spiked 
with an exogenous peptide (LVIDEPTK from bovine hepatoma-derived growth factor 
(HDGF)), which was used as an internal standard for chromatographic performance. 
Proteotypic peptides were selected by in silico digestion using MRM Pilot software 
(ABSciex©, Framingham, MA, USA). Peptides containing cysteine or methionine 
residues were excluded. Three to five transitions were programmed for each peptide: 
EFTPPVQAAYQK, LHVDPENFR, LLVVYPWTQR, SAVTALWGK, 
VLGAFSDGLAHLDNLK and VNVDEVGGEALGR for Hemoglobin B-Human. SRM 
experiments were performed on a 5500 QTRAP hybrid triple quadrupole/linear ion trap 
mass spectrometer (ABSciex©, Framingham, MA, USA) as described elsewhere [28]. 
Data analysis was performed using Analyst 1.5.2 and MultiQuant 2.0.2 software 
(ABSciex©, Framingham, MA, USA).The mean area of all transitions was obtained for 
each peptide. The value of area ratio (analyzed peptide/exogenous peptide) was 
calculated.  
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Variations in the levels of 33 peptides using the corresponding standards [29] that were 
spiked into each trypsin digested plasma sample (Supplementary Table 1), were 
monitored in a different laboratory using similar conditions (Supplementary Material 1). 
Data analysis was performed with Skyline [30]. 
 
 
WESTERN BLOT  
 
20 µg of non-depleted pooled samples were loaded into pre-cast tris-gly gels AnyKD 
(Bio-Rad Laboratories Inc
©
, Hercules, CA, USA).  After electrophoresis, the gels were 
incubated in transfer buffer (Bio-Rad Laboratories Inc
©
, Hercules, CA, USA) for 10 
min.  Transfer was performed in a Bio-Rad minitransfer system using a PVDF                           
membrane previously activated with methanol for 1.5 h at 200 mA.  After transfer, the 
gels were fixed in 40% ethanol / 10% acetic acid and stained. Membranes were blocked 
overnight with 5 % BSA (Roche Diagnostics
©
, S.L, Basilea, Switzerland) in TBS buffer 
(Bio-Rad Laboratories Inc
©
, Hercules, CA, USA) at 4º C. Membrane washing was 
performed with TBS buffer–Tween20 (5%). The primary antibodies were monoclonal 
antibodies anti-Apo A1 (Santa Cruz Biotechnology, Inc
©
, Dallas, TX, USA), anti-
kininogen 1 (Abcam
©
, Cambridge, UK) and anti-vitronectin (Abcam
©
, Cambridge, UK) 
all diluted in 5% TBS-Tween20. 
 
RESULTS  
 
Immunodepletion of plasma samples prior to proteomic analysis 
 
Factors in handling samples that we assessed by proteomic analyses were the influence 
of time from blood collection to plasma isolation, less than 4 h at RT or after a delay of 
24 h at 4°C, and the effect if 1, 2 or 3 freeze/thaw cycles. Prior to proteomic analysis, 
we subjected the plasma pools to chromatographic immunodepletion because this extra 
step permits wider coverage of the proteome of serum and other physiological fluids 
[31,32]. Initial preparatory experimental proofs showed a highly reproducible pattern of 
the depletions with no carry-over between injections (data not shown). Analytical 
injections were done randomly and blanks were inserted between samples. 
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Solid Phase Extraction (SPE) and MALDI-TOF MS analysis 
 
MALDI-profiling was used to find alterations in the mass patterns of the four pooled 
plasma samples studied. In all cases, the coefficient of variation (CV) during the 
extraction process and between the technical replicates did not exceed 21% and 6%, 
respectively (data not shown); this is in agreement with previous reports [21,33].  
 
The results, corresponding to a 1000-30000 Th. window, are represented in Figure 2. 
The spectral representation of the C4-enriched fraction showed no visible differences 
among the four samples (Fig. 2A). A principal component analysis (PCA) (Fig. 2B) did 
not reveal any significant segregation or hierarchical clustering, although some subtle 
differences were observed for the P24.D1 sample. 
 
The spectral representation of the C18-enriched fractions demonstrated, as expected, a 
decrease in the number of peaks in the 10000-30000 Th. range and an increase in the 
1000-10000 Th. range (Fig. 2C). Again, no significant differences were detected among 
the four samples and no segregation or hierarchical clustering was observed after PCA 
analysis (Fig. 2D). 
 
To summarize, defrost cycles in the samples tested using the MALDI-Profiling SPE 
with prior enrichment by reverse phase C4 or C18 resins showed no significant 
differences in the observed spectra profiles. Slight non significant differences were 
detected in the P24.D1 samples, suggesting that minor alteration in the proteins present 
in the plasma might occur after a 24-hour delay in processing. 
 
 
Differential in gel electrophoresis (DIGE) and selected reaction monitoring (SRM) 
analysis suggest that hemolysis occurs after delay in the processing of the initial 
blood samples 
 
The DIGE analysis was expected to detect plasma protein degradation, through the 
detection of increasing or decreasing spot intensities in the bi-dimensional gel 
electrophoresis protein map. The image analysis of the results (Fig. 3A) showed several 
low molecular weight isoforms appearing to be significantly more abundant in P24.D1 
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samples. Only four of these spots were identified by mass spectrometry (LC-MS/MS), 
corresponding to different isoforms of hemoglobin chains (Fig. 3B and 3C). These 
results would suggest that there is no proteolytic degradation associated with 
freeze/thaw cycles, although a certain degree of hemolysis can occur after a 24-hour 
delay in the sample processing. 
 
To validate these results, we performed SRM assays for hemoglobin B, which was the 
hemoglobin-related protein detected in the DIGE experiment with the highest MS/MS 
score. Six out of 13 putative proteotypic peptides were observed (Fig. 4A) in the 
enhanced resolution mode, and were subsequently used for quantification in the MRM 
mode. Quantification of the selected peptide areas (Fig. 4B and 4C) indicate that 
hemoglobin B is more abundant in the P24.D1 sample, thus confirming the DIGE 
results. 
 
Isobaric tags for relative and absolute quantification (iTRAQ) analysis 
 
iTRAQ technology was used for relative quantification of plasma proteins. Variation in 
protein abundance between samples would, if significant, suggest proteolytic 
degradation or the presence of undesired proteins. Results are presented in 
Supplementary Data 1. The concentrations of several typical serum proteins detected 
were relatively modulated among the different samples, as presented in the 
quantification summary.  
 
Selected Reaction Monitoring (SRM) using peptide standards  
 
Because a significant number of common plasma proteins were detected as modulated 
by the iTRAQ analysis, we decided to use a previously described peptide standard kit 
developed by the Borchers group [34] to validate a large number of proteins in the 
original non-depleted pooled samples using SRM (Fig. 5). In a single experiment, 37 
proteins were tested using a single proteotypic peptide per protein (Fig. 5A). In the four 
different samples tested, 33 proteins were detected and accurately quantified (Fig. 5B). 
The logarithmic representation of the heavy/light ratio suggests no major changes 
occurred in the amount of the proteins among the samples. A comparison of the 
individual ratios of each peptide with the average ratio of all the peptides 
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(Supplementary Data 2) revealed a group of six proteins, alpha-1-b-glycoprotein, 
apolipoprotein CIII, serotransferrin, vitronectin, alpha-2-microglobulin, and plasma 
retinol binding protein, whose profiles differed slightly from the average profile. 
 
Analysis of low molecular weight proteins 
 
If the integrity of plasma samples would be compromised, we would expect the 
appearance of protein fragments with lower molecular weight than the whole protein. 
Thus, fractionation of plasma proteins by SDS/PAGE should reveal a mobility shift of 
proteins due to the presence of fragments. In accordance, the number of identified 
proteins with higher molecular weight than expected in a gel slice should increase if 
plasma quality decreases. We fractionated complete and depleted plasma samples by 
SDS/PAGE and analyzed the low molecular weight (< 20 kDa) region of the gel. The 
identified proteins were arranged by their predicted molecular weight according to their 
sequence and grouped by quartiles (Supplementary Data 3). A slight but not significant 
increase in the number of identified proteins was observed in samples P4.D3 and 
P24.D1 of depleted plasma. However, there was no difference among the protein size 
groups (Fig. 6A and 6B), suggesting that the number of fragments from larger proteins 
is not increased by any of the treatments. It could be that the number of identified 
proteins would remain unchanged but with more peptides assigned to them, which 
would lead to an increase in their protein coverage.  To assess this possibility, we 
determined the protein coverage of each protein size group (Fig. 6C and 6D). The data 
did not show any significant change in protein coverage among samples in any protein 
size group. Overall, the results indicated that the treatments did not affect significantly 
the integrity of plasma proteins.  Although global changes were not observed, some 
individual proteins, particularly apolipoprotein B100 (ApoB100), appeared to increase 
their coverage in depleted plasma samples P4.D3 and P24.D1. We investigated the 
abundance of ApoB100 by western blot and SRM analysis but the results did not 
confirm any significant difference (not shown). 
  
LC-MALDI-TOF/TOF and western-blot validation of selected proteins 
 
After protein identification using Mascot, the emPAI score [27] was used to estimate 
the absolute amount of each protein in a particular sample (Supplementary Data 4). 
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Changes in the emPAI score would have revealed protein degradation or the presence of 
truncated isoforms. Fig. 7 represent the average emPAI score (Y axis) of all the proteins 
detected (X axis) fast (t≤4h) vs. delayed (t=24h) processing (Fig. 7A) or when 
comparing freeze/thaw cycles (Fig. 7B). 
 
The average emPAI score did not vary for most proteins when the samples were 
compared. However, among the few exceptions detected, suggesting that the amount of 
these proteins might vary among samples, three were selected (apolipoprotein A1, 
vitronectin and kininogen 1) for western blot validation in crude pooled samples. The 
results of this analysis did not reveal accumulation or degradation of the proteins (Fig. 
7C and 7D).  
 
DISCUSSION 
 
An increasing number of clinical biobank sample collections from large-scale 
population-based studies are currently available for research applications. Many 
proteomic studies for biomarker discovery have been developed based on access to 
these collections [35]. However, standardization of sample quality is a critically 
important requirement for valid use of the full potential of the collected samples [36]. 
The need for improved biomarker research has focused attention on the effects of pre-
analytical variable on collected samples as key parameters determining the obtained 
results [37]. Although this is particularly true for plasma profiling studies, the stability 
of most plasma proteins to pre-analytical variables remains unexplored. 
 
Biobanking faces standardization of a wide range of pre-analytical variables involved in 
sampling procedures of blood and plasma. Among these, acquisition, handling and 
storage may produce alterations of the proteome. In this work, we analyzed the 
influence of time from blood collection to plasma isolation (less than 4 h at RT or after 
a delay of 24 h at 4°C) and the number of freeze/thaw cycles (1, 2 or 3) performed on 
plasma samples using several standardized proteomic techniques: (SPE MALDI-TOF, 
DIGE, iTRAQ, LC-MS/MS or LC-MALDI-TOF/TOF) and targeted proteomic analysis 
(SMR) platforms. We systematically evaluated the effects in prospectively collected 
human platelet-poor plasma from a representative population of 100 healthy donors (as 
defined by pre-established criteria) divided by gender (50%) and by age group (20 to 
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40, 40 to 60, and 60 to 80 years). The proteomic comparisons were based on differences 
in mean intensity values of peptides/protein using plasma processed under the different 
conditions.  In general, following a thorough analysis of the results from the different 
analytic techniques, no detectable significant changes were observed as a result of delay 
in blood processing or number of freeze/thaw cycles.  
 
The Biospecimen Reporting for the Improved Study Quality (BRISQ) has released 
recommendations on collection and management of human biospecimens [38]. 
According to these guidelines, all samples included in our study were handled 
identically by the biobank participants to exclude any pre-variable besides those we 
wanted to analyze. We followed the recommendation and used platelet-poor plasma to 
prevent the effects of activation of platelets [12]. 
 
Samples collected for clinical analysis are either used immediately or stored in biobanks 
for future research use. Unfortunately, biobanks where samples are processed and stored 
are often not close to the clinic where samples are collected. Thus, geography can delay 
the processing of blood samples for hours or even days; this interval could produce 
alterations in the proteome due to cell metabolism and activation [39]. To determine the 
extent of these alterations, we examined the effects of elapsed time to processing from 
venipuncture and the temperature at which samples are maintained prior to first 
centrifugation. It is deemed essential that the time elapsed between blood acquisition 
and processing in the biobank be as short as possible (less than 4 h, when possible), but 
sometimes blood samples cannot be processed until the day following extraction; in this 
case it is recommended that samples be maintained at low temperature to minimize 
proteolytic activity. However, the extent to which time and temperature can affect blood 
samples remains unclear. Our results indicate that few non significant changes occurred 
in peptide and protein identifications in plasma from blood collected in EDTA-plasma 
tubes and processed within the first 4 h following collection or after storage for up to 24 
h at 4°C prior to plasma isolation. The distribution of proteins in all samples was very 
similar, and the only clear difference observed by DIGE was in the concentration of 
several hemoglobin isoforms when there was a delay in blood centrifugation. This 
finding has been further confirmed by targeted MRM analysis, and is in accordance 
with other studies demonstrating by mass spectrometry that the undesired presence of 
high levels of hemoglobin chains in biological fluids could be used as marker for blood 
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contamination [40]. Also, in a previous study specifically examining serum handling 
conditions over several hours, both transport time and temperature were found to affect 
SELDI profiles [41]. In that study, the effects of time delay were minimized in samples 
transported on ice, although, as demonstrated by our results, hemoglobin also displayed 
significant variability. Comparable results were obtained after time course studies on 
plasma from blood collected in EDTA-plasma tubes and stored for up to a week either 
at 4°C or room temperature prior to plasma isolation. These proteomic studies revealed 
few significant changes in peptide and protein identifications, semitryptic peptides and 
methionine-oxidized peptides [42]. Results obtained by Hassis et al. [43], utilizing 
iTRAQ, are in agreement that minimal impact of time and temperature on plasma 
occurred after specimen collection. In serum, other previous studies have demonstrated 
that a blood pre-centrifugation delay of 24 h at room temperature influenced the proton 
NMR spectroscopic profile, but, if during this delay the temperature is held at 4°C, there 
was no influence on the proton NMR spectroscopic profile [44]. However, Findeisen et 
al [45] proposed a “proteomics degradation clock” based in the monitoring of synthetic 
spiked reporter-peptides, since their concentration in both serum and plasma samples 
decay in a time-dependent manner along a 2 to 24 hours period.   
 
Another pre-analytical variable possibly affecting stability of plasma is the number of 
freeze/thaw cycles. There is no consensus on the effects of freezing and thawing on 
serum and plasma. The marked effects and dependence on the number of freeze-thaw 
cycles on serum profiles generated using magnetic bead-based SPE followed by 
MALDI-TOF has been shown [46], and repeated freeze-thaw cycles resulted in a trend 
towards increasing changes in peak intensity in MALDI-TOF studies [47]. However, 
other studies of serum samples reported minimal effect on detected peaks of repeated 
freezing and thawing of up to ten cycles, as only minor effects were seen on the 
proteome, based upon the analysis of about 100 peaks by MALDI-TOF MS [48] and 
similar results were obtained in analyses of plasma subjected to up to 25 freeze/thaw 
cycles [42].  In agreement with the latter report, our data indicate that up to three 
freeze/thaw cycles have no significant effect on the stability of proteins in the plasma 
samples. 
 
Overall, our results indicate that the integrity of proteins and peptides was resistant to 
alteration by the pre-analytical variables considered in this study. Although there are 
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other studies related to protein stability of clinical samples with similar results, what is 
remarkable about our work is the large number of plasma samples examined and that 
our analyses assessed protein integrity by combining a wide set of complementary 
proteomic approaches performed at different proteomic platform participating 
laboratories that all yielded similar results. Thus, we were able to examine the stability 
at both the peptide and protein level of a far broader range of plasma proteins than 
previously possible using individual techniques and fewer specimens. The peptide-level 
analyses performed in our work provide a robust method for accurate protein 
quantization in plasma samples and a better understanding of the changes in proteins 
induced by delayed processing or plasma freeze/thaw cycles. We believe our study is 
the most comprehensive performed to date to determine the changes in proteins induced 
by delayed sample processing and plasma freeze/thaw cycles. 
 
This work indicates that the reevaluation of plasma collection protocols in clinical 
proteomics studies used to analyze biomarkers should be considered. Our data suggest 
that stability of plasma proteins under expanded clinical laboratory storage conditions 
(4°C for up to 24 h prior to sample processing) could be considered as an acceptable 
time frame for plasma collection. Thus, this sampling-preparation time frame could 
expand the current typical standard operating procedure (processing within 4 h of 
collection). In addition, the utilization of plasma samples subjected to up to three 
freeze/thaw cycles, at least in the case of controlled thawing times of no more than one 
hour, could be considered potentially acceptable for clinical proteomics studies. 
 
CONCLUSION 
 
In summary, although it is evident that pre-analytical variables may influence clinical 
proteomic studies using plasma, and these must be taken into account, the results of the 
present work indicate that blood proteins in plasma are broadly insensitive to such pre-
analytical variables as delayed processing or freeze/thaw cycles when analyzed at the 
peptide level. These findings do not mean that these pre-analytical variables do not 
affect other analyses, for instance, immunoassays directed at intact proteins, where 
collection protocols may have different requirements.  
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Figure 1: Work-flow for sample preparation and analysis.  
Blood samples were processed following standard procedures with less than four hours 
of delay after extraction (P4: t≤4h) and subjected to 1, 2 or 3 freeze/thaw cycles. 
Alternatively, blood samples were processed following a 24-hour delay (P24) at 4ºC. 
Samples were pooled and immuno-depleted to obtain the flow-through fraction enriched 
in lower-abundance proteins. Frozen samples were then distributed to the participating 
laboratories. 
 
Figure 2: Solid phase-extraction (SPE) and MALDI-TOF MS analysis of C4 and 
C18-extracted depleted samples. 
A, C) MALDI profiling of (A) C4- and (C) C18-extracted pools. The diagrams 
represent the intensity of the signal (Y axis, arbitrary units) along the correspondent 
mass window (X axis, Th) of the different technical and experimental replicates (Z 
axis). B, D) Principal component analysis (PCA) of (B) C4- and (D) C18-extracted 
pools to reveal putative segregation and hierarchical clustering of the samples. 
 
Figure 3: Differential in gel electrophoresis (DIGE) of depleted samples. 
A) Representative two-dimensional DIGE image of the samples showing spots 
designated as modulated following software analysis. B) Table summarizing the 
characteristics of the four identified spots. C) Relative abundance of the four identified 
spots comparing the different analyzed samples. 
 
Figure 4: Multiple reaction monitoring (MRM) analysis of hemoglobin B. 
A) List of theoretical proteotypic peptides generated with MRM Pilot software and the 
exogenous spiked peptide LVIDEPTK. B) Area ratio (corrected) expressed in arbitrary 
units corresponding to the six observed peptides in the four different analyzed samples. 
C) Numerical values corresponding to the corrected area ratio. LC=liquid 
chromatography; MS=mass spectrometry 
 
Figure 5: Multiple reaction monitoring (MRM) analysis using peptide standards of 
selected plasma proteins. 
A) Table showing the proteotypic peptides for the thirty-seven selected proteins tested 
in parallel. B) Graphical logarithmic representation of the heavy/light ratio for the 
thirty-three observed proteins (X axis) in the four different analyzed samples. 
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Figure 6: Analysis of plasma proteins integrity. 
A, B) The number of identified proteins in the low molecular weight region of a 
SDS/PAGE of (A) depleted and (B) complete plasma. C, D) The protein coverage of the 
identified proteins in the low molecular weight region of a SDS/PAGE of  (C) depleted 
and (D) complete plasma, respectively. Median molecular weight of quartiles 1-4: 14, 
29, 53, and 93 kDa for depleted plasma; and 11, 34, 53, and 82 kDa for complete 
plasma. 
 
Figure 7: LC-MALDI-TOF/TOF and western-blot validation of selected proteins. 
A) Average emPAI index (Y axis) of all the proteins detected (X axis) when comparing 
fast processing (P4) vs. delayed processing (P24). B) The average emPAI (Y axis) of all 
the proteins detected (X axis) when comparing freeze/thaw cycles. C) Western blot 
validation of the putative alteration of the amount of selected proteins, apolipoprotein 
A1, vitronectin and kininogen. D) Densitometry analysis of each protein normalized to 
the corresponding densitometry of the Ponceau staining (not shown) of the entire lane. 
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HIGHLIGHTS 
 The integrity of proteins is resistant to alteration by the preanalytical variables  
 Up to three freeze/thaw cycles have no effect on the integrity of proteins in 
plasma 
 Delayed processing of blood has no significant effect on the stability of proteins  
